Trials / Completed
CompletedNCT00089973
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to Ispinesib? 2. What are the side effects of Ispinesib? 3. How much Ispinesib is in the blood at specific times after it is taken?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ispinesib | Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2). |
Timeline
- Start date
- 2004-06-30
- Primary completion
- 2006-08-25
- Completion
- 2006-08-25
- First posted
- 2004-08-20
- Last updated
- 2018-02-26
- Results posted
- 2018-02-26
Locations
13 sites across 5 countries: United States, Belgium, Malaysia, Singapore, United Kingdom
Source: ClinicalTrials.gov record NCT00089973. Inclusion in this directory is not an endorsement.